MC3R: Melanocortin receptor 3
G protein-coupled receptor for melanocyte-stimulating hormones (alpha, beta, and gamma-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on MC3R, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Modimelanotide | Phase 2 | AbbVie | Protein or peptide | AgonistMelanocortin receptor 3 agonist | 0 |
- Obesity due to MC3R deficiency0.27
- Crush injury0.23
- Alcohol drinking0.22
- Fever of unknown origin0.20
- Arthropathy0.20
- Parasitic infectious disease0.17
- Acute tonsillitis0.17
- Obesity due to melanocortin 4 receptor deficiency0.11
- Tuberculosis0.09
- Obesity disorder0.09
- Abnormality of the skeletal system0.09
- Placenta praevia0.08
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4644, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P41968, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets